Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05530421 · ClinicalTrials.gov registry record · Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
A Phase 2 study of Relapsed and Refractory Multiple Myeloma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT05530421: Recruiting Phase 2 study of Relapsed and Refractory Multiple Myeloma, sponsored by University of Miami.
NCT05530421 is a Phase 2 study of Relapsed and Refractory Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05530421, a Phase 2 study of Relapsed and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
Primary Outcome
Overall response rate (ORR) will be reported as the fraction of participants achieving either complete response (CR) or partial response (ORR = CR + PR) to study treatment. Response to therapy will be assessed by treating physician using International Myeloma Working Group 2016 response criteria.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Selinexor
- DRUG Dexamethasone
Study Locations (3)
Florida
- University of Miami, Lennar Foundation Medical Center - Coral Gables
- University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- University of Miami, Sylvester Comprehensive Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-26 |
| Est. Completion | 2030-03-26 |
| Phase | Phase 2 |
What NCT05530421 shows while recruiting
NCT05530421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Relapsed and Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT05530421 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05530421 about?
NCT05530421 is a clinical study titled "Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma". The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
What is the current status of trial NCT05530421?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-03-26. Estimated completion is 2030-03-26.
What conditions does trial NCT05530421 study?
This clinical trial studies the following conditions: Relapsed and Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05530421?
The interventions under investigation include: Venetoclax (DRUG), Selinexor (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05530421?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05530421 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed and Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05530421's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI